DIABETOGENICIDAD DE LAS ESTATINAS
|
|
- Melanie Greer
- 5 years ago
- Views:
Transcription
1 DIABETOGENICIDAD DE LAS ESTATINAS Lluís Masana Marín Unidad de Medicina Vascular y Metabolismo Hospital Universitario Sant Joan Universidad Rovira i Virgili, IISPV, CIBERDEM REUS
2 Statins and diabetes Google search: About 7,600,000 results Pubmed search: 4096 In 2012 the U.S. FDA changed the wording on all statins except pravastatin; Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including 1 1. Zocor label. FDA update Reference ID: Available at Accessed April 2014
3 Increased risk of diabetes in JUPITER Analysis from JUPITER* (n=17,802) Event Monitored adverse events Rosuvastatin (N=8901) Placebo (N=8901) Any serious event no. (%) 1352 (15.2) 1377 (15.5) 0.60 Muscular weakness, stiffness or pain no. (%) 1421 (16.0) 1375 (15.4) 0.34 Myopathy no. (%) 10 (0.1) 9 (0.1) 0.82 Rhabdomyolysis no. (%) 1 (<0.1) 0 Newly diagnosed cancer no. (%) 298 (3.4) 314 (3.5) 0.51 Death from cancer no. (%) 35 (0.4) 58 (0.7) 0.02 Gastrointestinal disorder no. (%) 1753 (19.7) 1711 (19.2) 0.43 Renal disorder no. (%) 535 (6.0) 480 (5.4) 0.08 Bleeding no. (%) 258 (2.9) 275 (3.1) 0.45 Hepatic disorder no. (%) 216 (2.4) 186 (2.1) 0.13 Laboratory values Creatinine, >100% increase from baseline no. (%) 16 (0.2) 10 (0.1) 0.24 Glomerular filtration rate at 12 mo ml/min/1.73m Median Interquartile range Alanine aminotransferase >3xULN on consecutive visits no. (%) 23 (0.3) 17 (0.2) 0.34 Glycated haemoglobin at 24 mo - % P Value Median Interquartile range Fasting glucose at 24 mo mg/dl 0.12 Median Interquartile range Trace of glucose in urine at 12 mo no. (%) 36 (0.5) 32 (0.4) 0.64 Other events Newly diagnosed diabetes (physician-reported) no. (%) 270 (3.0) 216 (2.4) 0.01 Haemorrhagic stroke no. (%) 6 (0.1) 9 (.01) 0.44 Ridker et al. NEJM 2008;359(21): *JUPITER: Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
4 Statins increase the risk of T2D by 9% over 4 years (n=91,140) Decreased risk of diabetes Increased risk of diabetes Sattar et al. Lancet 2010; 375:
5 Incident diabetes Incident diabetes The Increased Risk of Diabetes Largely Occurs in Patients With 1 or More Risk Factor. Analysis from JUPITER* (n=17,603) Cumulative incidence of diabetes in those with or without 1 or more risk factors 0.15 No risk factors or more risk factors Rosuvastatin 20mg Placebo Rosuvastatin 20mg Placebo Follow up (years) Number at risk Rosuvastatin Placebo Follow up (years) Number at risk Rosuvastatin Placebo Population Deaths/CV events avoided New diabetes cases Those with no diabetes risk factors at baseline 86 0 Those with 1 or more diabetes risk factors at baseline Ridker et al. Lancet 2012;380: *JUPITER: Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
6 Patients with new onset diabetes (%) Independent Risk Factors for the Development of Diabetes with High Dose Atorvastatin Analysis from TNT* (n=7,595) Characteristic absent Characteristic present Fasting glucose >100 mg/dl Triglycerides >150 mg/dl BMI >30kg/m 2 History of hypertension Waters et al. JACC. 2011;57(14): *TNT: Treat to New Targets
7 % Patients with new onset diabetes Risk of T2DM with Atorvastatin is Strongly Correlated to the Presence of Risk Factors TNT HR=5.78 p< HR=2.04 p< HR=2.73 p< HR=1.64 p< Risk Factor Absent Risk Factor Present IDEAL HR=4.72 p< HR=1.88 p< HR=2.59 p< HR=1.60 p< SPARCL HR=3.49 p< HR=2.37 p< HR=2.36 p< HR=1.91 p< Waters et al. J Am Coll Cardiol 2011;57: FPG>100mg/dL TG>150mg/dL BMI>30mg/m 2 History of hypertension
8 The Risk of New-Onset Diabetes is Affected by the Number of Metabolic Risk Factors in Patients with Established CVD Risk factors Incidence % TNT *Trial (n=7,595) IDEAL* Trial (n=7,595) SPARCL* Trial (n=3,803) HR (95% CI) P value Incidence % HR (95% CI) P value Incidence % HR (95% CI) P value < < < < < < < < < < < Total Waters et al. JACC 2011;57:1535 *TNT: Treat to New Targets; SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels; IDEAL: Incremental Decrease in End Points Through Aggressive Lipid Lowering
9 The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice The diabetogenic effects of statins appear to be dose-related. N.A. Sattar et al. / Atherosclerosis Supplements 15 (2014) 1e15
10 Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study Shen L et al. BMJ 2013;347:f6745
11 HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials HMGCR gene, rs (for the main analysis) and Rs individuals from 43 genetic studies Swerdlow DI et al Lancet. September 24,
12 HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials Swerdlow DI et al Lancet. September 24,
13 Son todas las estatinas iguales?
14 Statins vary in chemical structure O HO CO 2 Na OH O HO O O HO CO 2 Na OH O O F N HO Pravastatin Simvastatin Fluvastatin HO - CO 2 OH HO - CO 2 OH HO - CO 2 OH F N Ca 2+ F Ca 2+ F Ca 2+ HN O N N N N S Atorvastatin Pitavastatin O 2 Rosuvastatin
15 Statins Exert Differential Effects on Insulin Sensitivity (IS) Among Non-diabetic Patients Pravastatin Koh (-0.088, 0.971) Sugyama (-0.144, 1.114) Gannage-Yared (-0.621, 0.621) Subtotal (0.032, 0.651) Atorvastatin Huptes (-0.929, 0.824) Stalenhoef (-0963, 0.333) Watts (-1.279, 0.412) Costa (-0.379, 0.994) Chan (-0.844, 0.726) Subtotal (-0.243, 0.205) Rosuvastatin Kastaganos (0.474, 0.243) Sviridov (0.512, 0.645) Ooi 2007a (-1.008, 0.952) Ooi 2007b (-1.060, 0.901) Tar Avest (0.727, 0.560) Stalenhoef (-0.357, 0.345) Subtotal (-0.223, 0.148) Simvastatin Koh (-0.902, 0.143) Koh 2008a (-1.303, 0.274) Koh 2008b (-1.429, 0.146) Koh 2008c (-1.288, 0.282) Koh 2008d (-1.288, 0.282) Devaraj (-0.336, 0.776) Altunbas (-1.614, 0.285) Jula (-0.613, 0.106) Subtotal (-0.526, 0.117) Excluding Pravastatin (-0.284, ) Overall (-0.210, 0.042) Meta analysis of 16 placebo-controlled trials among non-diabetics involving atorvastatin, pravastatin, rosuvastatin or simvastatin (n=1146) Pravastatin significantly improved IS [SMD (95% CI ); p=0.03] Simvastatin significantly worsened IS [SMD (95% CI to 0.117); p=0.03] Standarized mean difference (95% CI) Baker et al. Diabetes Res Clin Pract Jan;87(1):
16 Short-Term Effect of Pitavastatin Treatment on Glucose Metabolism Kakuda H et al. Cholesterol. 2013;2013: doi: /2013/ Epub 2013 Dec 10.
17 Changes in blood glucose after 12 and 44 weeks of Pitavastatin or Atorvastin treatment Gumprecht J et al DIABETES, OBESITY AND METABOLISMVolume 13 No. 11 November 2011 doi:
18 HbA1c (%) HbA1c Levels Significantly Decrease Over Time with Pitavastatin in Japanese Patients with T2DM Post marketing survey (n=1,843) ± ± ± Mean±S.D. p<0.001(repeated measures ANOVA) 3 month 6 month 1 year 2 year 3 year 4 year 5 year Teramoto T et al. Jn Pharmacol Ther 2011;39:
19 J-PREDICT: First Prospective Trial to Evaluate Statin-induced T2DM in an At-Risk Population An open-label randomised controlled study to evaluate the effect of pitavastatin on new onset of diabetes in a population with impaired glucose tolerance (IGT) Study hypothesis: The treatment group receiving pitavastatin 1 2 mg/day will show a lower incidence of new-onset diabetes compared with the control group receiving lifestyle modification alone Yamazaki et al. Diabetol Int Published online August
20 Design and Methods 1240 adult patients with IGT (WHO criteria) Randomly assignment in a 1:1 ratio to either lifestyle modification (control) or pitavastatin 1 2 mg/day in addition to lifestyle modification Pre-screening IC Screening 75-g OGTT Randomisation Lifestyle intervention alone Lifestyle intervention+ pitavastatin 1 2 mg/day < 6 months <2 months 60 months (max.108 months) WHO IGT criteria: 2h plasma glucose 140 and <200 mg/dl and fasting plasma glucose <126 mg/dl Yamazaki et al. Diabetol Int Published online August
21 Study recruitment Assessed or eligibility (n=8,472) Screening (n=3,462) Randomisation (n=1,269) Excluded (n=5,010) Did not meet screening criteria (n=1,303) Refused to participate (n=3,512) Other reasons (n=138) Excluded (n=2,193) Did not meet screening criteria (n=1,619) Refused to participate (n=572) Other reasons (n=2) Allocated to lifestyle modification only (n=635) Allocated to Pitavastatin 1-2 mg/day (n=634) Yamazaki et al. Diabetol Int Published online August
22 Cumulative Incidence Rate Pitavastatin reduced the incidence of diabetes by 18% after a median of 2.8 years HR 0.82 (95% CI: ) p=0.041 (Stratified log-rank test) Control 0.50 Pitavastatin No. at Risk Control Pitavastatin Months since randomisation Median follow up 2.8 years (range 2-6 years) Average pitavastatin dose 1.3mg html73rd ADA 2013, Chicago, IL, USA: Late Breaking Studies 61-LB
23 The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice N.A. Sattar et al. / Atherosclerosis Supplements 15 (2014) 1e15
24 The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice Recommendations for glycaemia testing pre- and post- statin commencement in individuals without known diabetes N.A. Sattar et al. / Atherosclerosis Supplements 15 (2014) 1e15
25 Conclusiones El efecto beneficioso de las estatinas sobre el riesgo cardiovascular supera sus posibles efectos adversos Las estatinas tienen diferencias a nivel molecular que condicionan su farmacocinética y farmacodinámica. Estas diferencias moleculares pueden comportar una distinta interacción con el metabolismo glucídico Ciertas estatinas (P-P) parecen tener un efecto neutro singular sobre el metabolsimo glucídico.
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationSeung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital
Novel Statin Strategy to Prevent Atherosclerotic Cardiovascular Disease in Diabetic Patients-Curtailing Heart Attack : Korean Data and JUPITER again in spotlight Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI,
More informationStatins and New Onset Diabetes Mellitus NPO
Learning Objectives 1) Recognize the risk of diabetes associated with statin therapy in a population at high risk for diabetes 2) Compare and contrast statin benefit to risk when treating patients in a
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationFemale, years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at
Female, 51-70 years or younger BMI of 30 or less at time of Diabetes diagnosis Prefer no family history of diabetes Took Lipitor consistently for at least two months prior to diagnosis or within six months
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationREAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease
REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationQué factores de riesgo lipídicos debemos controlar? En qué medida?
Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationZEUS Trial ezetimibe Ultrasound Study
Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationPreventing Diabetes K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y
Preventing Diabetes 2018 K A R O L E. W A T S O N, M D, P H D, F A C C P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y D A V I D G E F F E N S C H O O L O F M E D I C I N E A T U C L A CO-DIRECTOR,
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSeung-Hwan Lee, M.D., Ph.D.
2015.10.16. ICDM, DMJ session Statin discontinuation after achieving a target low-density lipoprotein cholesterol level in type 2 diabetic patients without cardiovascular disease: a randomized controlled
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationAspectos diferenciales entre estatinas y su aproximación a la práctica clínica
Aspectos diferenciales entre estatinas y su aproximación a la práctica clínica Lluís Masana Marín Unitat de Medicina Vascular i Metabolisme Servei de Medicina Interna Hospital Universitari Sant Joan IISPV.
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP
Diabetes Update: Diabetes Management In Primary Care Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Critically evaluate the evidence emerging within diabetes research as it applies to recommendations
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationThe Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C
The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationStatins. In Utero to Death and Everything In-Between. Bryce M Kayhart, PharmD, BCPS MFMER slide-1
Statins In Utero to Death and Everything In-Between Bryce M Kayhart, PharmD, BCPS 2017 MFMER slide-1 Disclosures I have no financial relationships related to the material of this presentation to disclose.
More informationCardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy
Journal of the American College of Cardiology Vol. 61, No. 2, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.042
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationTreating dyslipidemia
Treating dyslipidemia in patients with type 2 diabetes mellitus 18 The Nurse Practitioner Vol. 40, No. 18 www.tnpj.com 2.0 CONTACT HOURS 1.0 CONTACT HOURS Abstract: Type 2 diabetes mellitus is associated
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationARTICLE. Henna Cederberg & Alena Stančáková & Nagendra Yaluri & Shalem Modi & Johanna Kuusisto & Markku Laakso
Diabetologia (215) 58:119 1117 DOI 1.17/s125-15-3528-5 ARTICLE Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationS Ramakrishnan. Secretary CSI DB & PCSI. Executive Editor, Indian Heart Journal. Published 100 papers in indexed journals
S Ramakrishnan MD, DM, FACC Additional Professor of Cardiology AIIMS, New Delhi Secretary CSI DB & PCSI Executive Editor, Indian Heart Journal Published 100 papers in indexed journals Awarded DP Basu award,
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationTriglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationPravastatin conversion to atorvastatin
P ford residence southampton, ny Pravastatin conversion to atorvastatin Pravastatin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationLipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011
Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier,
More informationSTATINS ARE DANGEROUS DRUGS. Statins actually increase the risk of heart attacks and strokes. (!!!)
STATINS ARE DANGEROUS DRUGS Statins actually increase the risk of heart attacks and strokes. (!!!) Statins cause Type 2 Diabetes. Statins cause memory loss and cognitive decline. Statins destroy muscle
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationThe Efficacy and Safety of Statins in the Primary Prevention of Cardiovascular Disease
University of North Dakota UND Scholarly Commons Physician Assistant Scholarly Project Papers Department of Physician Studies 2018 The Efficacy and Safety of Statins in the Primary Prevention of Cardiovascular
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More information